Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342444 · ClinicalTrials.gov registry record · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
A Phase 4 study of Surgery and Trauma, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 606
- Enrollment target
- 1
- Study location
NCT02342444 is a Phase 4 study of Surgery and Trauma that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 606 participants, below the 52,847-participant average among 120 other Surgery trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02342444, a Phase 4 study of Surgery and Trauma, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 606 participants
- Enrollment target
- 1
- Study location
Study Summary
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox) is given to patients who are at a higher risk of developing clots in their legs or lungs. There are two standard doses of enoxaparin that are recommended by the drug companies. These two doses have never been directly compared in trauma, general, and vascular surgery patients. The purposes of this study are: 1. to compare the development of blood clots in patients receiving 30mg twice daily of enoxaparin compared to patients receiving 40mg once daily of enoxaparin. 2. to determine if there is higher risk of bleeding complications in patients receiving 30mg twice daily of enoxaparin compared to patients receiving 40mg once daily. Patients enrolled into the study will be randomized to receive enoxaparin, 30mg twice daily or enoxaparin, 40mg once daily. Patients will then be monitored for signs and symptoms of blood clots. At the time of discharge (or before, if medically indicated), an ultrasound test will be performed to look for blood clots in the patient's legs. The investigators will compare incidence of blood clots formed between the 2 groups of patients to determine if one dose of enoxaparin relates to a lower rate of blood clots in critically ill patients. The investigators will also compare the incidence of bleeding complications between the 2 groups.
Conditions Studied
Interventions
- DRUG Enoxaparin Sodium Injection 30 mg BID
- DRUG Enoxaparin Sodium Injection 40 mg QD
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2014-02 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02342444
The ClinicalTrials.gov registry entry for NCT02342444 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 606 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52,847-participant average among 120 other Surgery trials with a reported enrollment target (99% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Surgery appearing as the primary indexed condition, and to 2 interventions - of which Enoxaparin Sodium Injection 30 mg BID is the first listed.
NCT02342444 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT02342444 about?
NCT02342444 is a clinical study titled "Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)". The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox) is given to patients who are at a higher risk of developing clots in their legs or lungs. There are two standard doses of enoxaparin that are recommended by the drug companies. T...
What is the current status of trial NCT02342444?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 606 participants. The study started on 2014-02. Estimated completion is 2025-03-31.
What conditions does trial NCT02342444 study?
This clinical trial studies the following conditions: Surgery, Trauma, Deep Vein Thrombosis (DVT), Thromboembolic Events.
What interventions are being tested in trial NCT02342444?
The interventions under investigation include: Enoxaparin Sodium Injection 30 mg BID (DRUG), Enoxaparin Sodium Injection 40 mg QD (DRUG).
Who is sponsoring clinical trial NCT02342444?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02342444 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial
RECRUITING · Phase 4
-
Continuous Versus Single Injection Adductor Canal Blocks for Outpatient Total Knee Arthroplasty
RECRUITING · Phase 4
-
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
RECRUITING · Phase 4
-
Transversus Abdominis Plane Block Compared to Local Anesthetic Wound Infiltration in Gynecologic Oncology Surgery
RECRUITING · Phase 4
-
Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial
RECRUITING · Phase 4
-
Multimodal Analgesia Effect on Post Surgical Patient
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.